ClinicalTrials.gg
Not yet recruitingNCT07881692GOT VOICEUpdated Oct 19, 2026

GOT VOICE GROUP SINGING

An interventional study of In-Person Group Singing and instructional sing-along video series in Elderly and Coronary Arterial Disease (CAD), sponsored by Medical College of Wisconsin. Not yet recruiting at 1 site in United States. Open to participants aged 55 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Medical College of Wisconsin · Not applicable, Interventional, and Other

Updated Oct 19, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
55 Years to 89 Years
Sex
All
01

Study summary

Unlike traditional physical exercise, the impact of singing on cardiovascular health has not been extensively studied. Endothelial dysfunction predicts cardiovascular events, and physical exercise improves vascular endothelial function. In a rigorously conducted randomized, cross-over control study, our team is the first to demonstrate that 30 minutes of solo singing improves endothelial function acutely, regardless of singing expertise. Changes were more robust in subjects with baseline endothelial dysfunction (i.e., those with established coronary artery disease). The improvements occurred in microvascular, but not macrovascular, endothelial function. The observed change in microvascular function translates into a \~25% reduction in cardiovascular disease (CVD) risk, which is comparable to traditional cardiac rehabilitation program participation.

Based on our prior research, the overall objective of the planned future RCT is to test our central hypothesis that habitual singing over several weeks, similar to habitual exercise, will lead to sustained and favorable vascular adaptation, thereby lowering CVD risk. The overall objective of this project, titled "GrOup singing or solo singing To improve Vascular health in Older adults wIth Coronary artery disEase (GOT VOICE): A Feasibility Study", is to refine and protocolize the singing interventions and test the feasibility of our future trial design.

02

Conditions studied

  • Elderly
  • Coronary Arterial Disease (CAD)

Keywords

  • Group Singing
03

In context

Lead sponsor

Medical College of Wisconsin is the lead sponsor of 546 studies on the registry; 120 are open to participants now.

Of its 74 completed or terminated interventional studies of FDA-regulated products, 57 (77%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects ≥55 up to 89 years old
  • Known history of stable coronary artery disease (over 1 year out from a coronary stent, myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting)

Exclusion criteria

Exclusion Criteria:

  • Parkinson's disease or tremor, upper arm fistula, or fingernail onychomycosis (all impact assessment of vascular function at the fingertips), pregnancy, current tobacco use, current illicit drug use, current excessive alcohol use (defined as more than 14 drinks/week for women, more than 28 drinks/week for men), more than mild cognitive impairment (as documented in the medical record by patient's treatment teams) or inability to follow study procedures, and non-English speaking.
  • Baseline hearing will be assessed with a tablet-based tool, which we have successfully used in the past. Those with severe hearing loss will be ineligible.
  • Participants cannot currently be enrolled in a traditional or intensive cardiac rehabilitation program.
  • Individuals with unstable cardiovascular conditions (e.g., uncontrolled arrhythmias, unstable angina, decompensated heart failure, or uncontrolled hypertension) will be excluded from participation.
  • Participants with severe or unstable respiratory disease, acute respiratory infections, or conditions that would limit safe participation in singing exercises will be excluded or discussed with their pulmonologist. For participants with stable chronic respiratory conditions, participation will be permitted provided symptoms are well managed and do not interfere with the ability to engage safely in the intervention. We made this decision because there is a substantial body of literature examining singing interventions in individuals with COPD, often under the title "Singing for Lung Health (SLH)." These studies generally report that singing is safe for people with stable COPD and may improve quality of life, breathing control, respiratory muscle function, and exercise tolerance.
  • Life expectancy is less than 2 years
  • Active malignancy
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Active comparator
    Group Singing

    Group singing sessions are conducted in an in-person format. Intake forms will be used to assess musical preference, prior music experience, and pertinent medical conditions to consider. Songs will be selected based on music preference of the subjects. At the start of each session, the music therapist will review the importance of singing and lead the group in taking deep breaths together. Throughout sessions, the therapist will encourage subjects to sing as much as possible, explaining that it's not about how they sound but how they feel. Initially, the group singing format will be 40 minutes of singing (includes a vocal warm-up), three times weekly, for a total of 12 weeks. The total singing time is the same as in the solo singing video arm. Based on focus group feedback, the formats could change. However, we will aim to keep total singing time the same (i.e., 120 minutes of singing per week). Each week, the group will also get a health education document to review.

    Behavioral: In-Person Group Singing

  • Active comparator
    Individual Sing-along Video Series

    Participants in this arm watch and sing to an online video series independently. The video series is created by a professor of voice with older students in the videos. We plan to use REDCap to deliver the assigned videos at set times and frequencies and display the videos in an embedded audio player for the subjects. Use of REDCap will allow us to track when subjects are watching the videos with reminders sent up to five times. We will also include 2 questions at the end on how much they enjoyed the video (scale 1-10) and how much of the 40 minutes were sung. Inserting questions at the end confirms that participants likely viewed the entire video. Each week, the group will also get a health education document to review.

    Behavioral: instructional sing-along video series

  • Active comparator
    Health Education Arm

    Participants receive a weekly health education document to review.

    Behavioral: Weekly health education

Interventions

  • BehavioralIn-Person Group Singing

    12-weeks of group singing in-person, 3 times weekly with additional weekly health education

  • Behavioralinstructional sing-along video series

    12-week solo singing video series done independently, 3 times weekly with additional weekly health education

  • BehavioralWeekly health education

    One health education topic will be provided for participants to review weekly in the form of a document

06

What researchers measure

Primary outcomes

  1. Participant adherence

    Participant attendance (out of 36 total sessions) by those enrolled

    Time frame: 12 weeks

  2. Retention rate

    Proportion of enrolled subjects who complete all 3 study visits during the 6 months of study participation.

    Time frame: 6 months

  3. Dropout rate (acceptability)

    Percent of enrolled subjects who drop out of study participation during the 12 weeks of active study participation

    Time frame: 12 weeks

07

Study locations

1 site
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
08

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07881692
Responsible party
Jacquelyn Kulinski (Professor of Medicine/Cardiology, Medical College of Wisconsin) — Principal investigator
First posted
Oct 19, 2026
Start date
Oct 31, 2026 (estimated)
Primary completion
Mar 1, 2029 (estimated)
Completion
Oct 31, 2029 (estimated)
Last update
Oct 19, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion